Cargando…
The Proteasome Inhibitor Bortezomib Induces an Inhibitory Chromatin Environment at a Distal Enhancer of the Estrogen Receptor-α Gene
Expression of the estrogen receptor-α (ERα) gene, ESR1, is a clinical biomarker used to predict therapeutic outcome of breast cancer. Hence, there is significant interest in understanding the mechanisms regulating ESR1 gene expression. Proteasome activity is increased in cancer and we previously sho...
Autores principales: | Powers, Ginny L., Rajbhandari, Prashant, Solodin, Natalia M., Bickford, Brant, Alarid, Elaine T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855213/ https://www.ncbi.nlm.nih.gov/pubmed/24339902 http://dx.doi.org/10.1371/journal.pone.0081110 |
Ejemplares similares
-
Proteasome inhibition represses ERα gene expression in ER+ cells- a new link between proteasome activity and estrogen signaling in breast cancer
por: Powers, Ginny L., et al.
Publicado: (2009) -
OR26-4 Genome-Wide Binding Profile of Phosphorylated Estrogen Receptor Reveals Association with Direct DNA Binding
por: Helzer, Kyle, et al.
Publicado: (2019) -
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015) -
The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013) -
Amping up estrogen receptors in breast cancer
por: Fowler, Amy M, et al.
Publicado: (2007)